Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 16;23(6):3199.
doi: 10.3390/ijms23063199.

Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)

Akshay Narkar  1   2 , James M Willard  2 , Ksenia Blinova  1
Affiliations
Review

Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)

Akshay Narkar et al. Int J Mol Sci. .

Abstract

Cardiomyocytes (CMs) differentiated from human induced pluripotent stem cells (hiPSCs) are increasingly used in cardiac safety assessment, disease modeling and regenerative medicine. A vast majority of cardiotoxicity studies in the past have tested acute effects of compounds and drugs; however, these studies lack information on the morphological or physiological responses that may occur after prolonged exposure to a cardiotoxic compound. In this review, we focus on recent advances in chronic cardiotoxicity assays using hiPSC-CMs. We summarize recently published literature on hiPSC-CMs assays applied to chronic cardiotoxicity induced by anticancer agents, as well as non-cancer classes of drugs, including antibiotics, anti-hepatitis C virus (HCV) and antidiabetic drugs. We then review publications on the implementation of hiPSC-CMs-based assays to investigate the effects of non-pharmaceutical cardiotoxicants, such as environmental chemicals or chronic alcohol consumption. We also highlight studies demonstrating the chronic effects of smoking and implementation of hiPSC-CMs to perform genomic screens and metabolomics-based biomarker assay development. The acceptance and wide implementation of hiPSC-CMs-based assays for chronic cardiotoxicity assessment will require multi-site standardization of assay protocols, chronic cardiac maturity marker reproducibility, time points optimization, minimal cellular variation (commercial vs. lab reprogrammed), stringent and matched controls and close clinical setting resemblance. A comprehensive investigation of long-term repeated exposure-induced effects on both the structure and function of cardiomyocytes can provide mechanistic insights and recapitulate drug and environmental cardiotoxicity.

Keywords: cardiomyocytes; cardiotoxicity; chronic; contractility; electrophysiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cardiotoxicity screening using human induced pluripotent stem cell (hiPSC) derived cardiomyocytes post prolonged exposures.
Figure 2
Figure 2
Potential cardiotoxicity mechanisms and chronic assay endpoints.
Figure 3
Figure 3
Mechanistic toxicity of anti-cancer drugs and drugs belonging to other indication areas.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S.Y., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0. - DOI - PMC - PubMed
    1. Park I.-H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-Specific Induced Pluripotent Stem Cells. Cell. 2008;134:877–886. doi: 10.1016/j.cell.2008.07.041. - DOI - PMC - PubMed
    1. Shi Y., Inoue H., Wu J.C., Yamanaka S. Induced pluripotent stem cell technology: A decade of progress. Nat. Rev. Drug Discov. 2017;16:115–130. doi: 10.1038/nrd.2016.245. - DOI - PMC - PubMed
    1. Moretti A., Laugwitz K.-L., Dorn T., Sinnecker D., Mummery C. Pluripotent Stem Cell Models of Human Heart Disease. Cold Spring Harb. Perspect. Med. 2013;3:a014027. doi: 10.1101/cshperspect.a014027. - DOI - PMC - PubMed
    1. Germanguz I., Sedan O., Zeevi-Levin N., Shtrichman R., Barak E., Ziskind A., Eliyahu S., Meiry G., Amit M., Itskovitz-Eldor J., et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J. Cell. Mol. Med. 2009;15:38–51. doi: 10.1111/j.1582-4934.2009.00996.x. - DOI - PMC - PubMed

LinkOut - more resources